129 related articles for article (PubMed ID: 38351310)
61. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
Cohen H; Bielorai B; Harats D; Toren A; Pinhas-Hamiel O
Pediatr Blood Cancer; 2010 May; 54(5):703-6. PubMed ID: 20063421
[TBL] [Abstract][Full Text] [Related]
62. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
[TBL] [Abstract][Full Text] [Related]
63. Pegaspargase-induced pancreatitis.
Alvarez OA; Zimmerman G
Med Pediatr Oncol; 2000 Mar; 34(3):200-5. PubMed ID: 10696127
[TBL] [Abstract][Full Text] [Related]
64. L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.
Top PC; Tissing WJ; Kuiper JW; Pieters R; van Eijck CH
Pediatr Blood Cancer; 2005 Jan; 44(1):95-7. PubMed ID: 15368548
[TBL] [Abstract][Full Text] [Related]
65. Ureteral obstruction caused by L-asparaginase-induced pancreatitis in a child with acute lymphoblastic leukemia.
Chen CH; Lu MY; Lin KH; Lin DT; Peng SF; Jou ST
J Formos Med Assoc; 2004 May; 103(5):380-4. PubMed ID: 15216406
[TBL] [Abstract][Full Text] [Related]
66. [Transient diabetes mellitus with ketoacidosis in a child during the treatment of acute lymphoblastic leukemia with L-asparaginase].
Skomra S; Przybylska T
Pol Tyg Lek; 1992 Jan 6-13; 47(1-2):31-2. PubMed ID: 1409032
[TBL] [Abstract][Full Text] [Related]
67. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
Lee JH; Lee J; Yhim HY; Oh D; Bang SM
J Thromb Haemost; 2017 Apr; 15(4):655-661. PubMed ID: 28150907
[TBL] [Abstract][Full Text] [Related]
68. [Acute pancreatitis secondary to L-asparaginase (a case report)].
Tazi I; Rachid M; Quessar A; Harif M; Benchekroun S
East Mediterr Health J; 2009; 15(2):475-9. PubMed ID: 19554997
[No Abstract] [Full Text] [Related]
69. Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia.
Liu C; Yang W; Devidas M; Cheng C; Pei D; Smith C; Carroll WL; Raetz EA; Bowman WP; Larsen EC; Maloney KW; Martin PL; Mattano LA; Winick NJ; Mardis ER; Fulton RS; Bhojwani D; Howard SC; Jeha S; Pui CH; Hunger SP; Evans WE; Loh ML; Relling MV
J Clin Oncol; 2016 Jun; 34(18):2133-40. PubMed ID: 27114598
[TBL] [Abstract][Full Text] [Related]
70. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Hijiya N; van der Sluis IM
Leuk Lymphoma; 2016; 57(4):748-57. PubMed ID: 26457414
[TBL] [Abstract][Full Text] [Related]
71. Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors.
Latoch E; Konończuk K; Taranta-Janusz K; Muszyńska-Rosłan K; Szymczak E; Wasilewska A; Krawczuk-Rybak M
Cancer Chemother Pharmacol; 2020 Dec; 86(6):741-749. PubMed ID: 33052454
[TBL] [Abstract][Full Text] [Related]
72. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
[TBL] [Abstract][Full Text] [Related]
73. Asparaginase-associated pancreatitis in children.
Raja RA; Schmiegelow K; Frandsen TL
Br J Haematol; 2012 Oct; 159(1):18-27. PubMed ID: 22909259
[TBL] [Abstract][Full Text] [Related]
74. Successful management of a child with asparaginase-induced hemorrhagic pancreatitis.
Lamelas RG; Chapchap P; Magalhaes AC; Filho JO; Mendes WL; de Camargo B
Med Pediatr Oncol; 1999 Apr; 32(4):316. PubMed ID: 10102033
[No Abstract] [Full Text] [Related]
75. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
Larson RA; Fretzin MH; Dodge RK; Schiffer CA
Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
[TBL] [Abstract][Full Text] [Related]
76. Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia.
Ishihara T; Nogami K; Ochi S; Ishida T; Kosaka Y; Sawada A; Inoue M; Osone S; Imamura T; Hosoi H; Shima M
Pediatr Blood Cancer; 2020 Jan; 67(1):e28016. PubMed ID: 31556233
[TBL] [Abstract][Full Text] [Related]
77. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
78. Ultrasound has limited diagnostic utility in children with acute lymphoblastic leukemia developing pancreatitis.
Richardson R; Morin CE; Wheeler CA; Guo Y; Li Y; Jeha S; Inaba H; Pui CH; Karol SE; McCarville MB
Pediatr Blood Cancer; 2021 Jan; 68(1):e28730. PubMed ID: 33111506
[TBL] [Abstract][Full Text] [Related]
79. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
[TBL] [Abstract][Full Text] [Related]
80. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
Farrell K; Fyfe A; Allan J; Tait RC; Leach M
Leuk Lymphoma; 2016 Nov; 57(11):2568-74. PubMed ID: 27078747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
